Member Info for Retireby40

there should be a lot of buying into the close with an RNS expected at 7am or 5pm on Monday ahead of the presentation. The CEO is talking a fair bit on twitter today and it’s all positive and a massive opportunity for SKIN, all this morning -

The #SKIN ecosystem is a complex environment with a diverse and individual microbial community and microbes. Volunteer human test sampling is no longer good enough.

The capital cost of instrumentation, recruiting suitable panels of volunteers and executing the #SKIN study is beyond the means of many companies. Or is that about to change? #integumen

The most successful #SKIN care brands at all price points are those that use R&D to generate advanced formulations and back up their products claims with scientific proof.

Traditional #SKIN care that focused on eradicating microbes, or skin bacterial flora, no longer applies. Skincare products should preserve a healthy skin microbiome and their effect should be tested in clinical trials to determine the real-life consumer benefit

CEO -
The capital cost of instrumentation, recruiting suitable panels of volunteers and executing the #SKIN study is beyond the means of many companies. Or is that about to change? #integumen

The most successful #SKIN care brands at all price points are those that use R&D to generate advanced formulations and back up their products claims with scientific proof.

From the CEO we’ve had a few clues re news on Monday. He said it’ll be pointless to hold it without news in addition to the recent podcasts so we can expect to hear something above and beyond what we’ve already heard.
There was also this quote from a blog -

Now there are hundreds, if not thousands, of products that need a quick solution to allow their products to stay on the shelves and that requires a fast-track approach I expect Labskin will be announcing a disruptive solution to address this in the Clinical research space shortly

Followed by these tweets yesterday.

#SKIN turnaround complete. Now it's full steam ahead for #integumen and as you say we are only showing the tip of the iceberg

It’s all about timing for #SKIN. It works when all the stars are alligned and 13 is not unlucky for everyone ?

News on Monday re a new solution in the clinical research space?

Gerry tweet replying to someone who bought in at IPO
EIS after tax is 3.5p then depending on averaging down #SKIN team have to deliver on what we set out to do. So far we are ahead of my expectations and moving ahead at some pace

given Gerry covered a lot in the podcasts which were great.
Hopefully whatever he’s planning is signed off before Monday as that’d be great. Remember this is a quote from a blog -
https://lemminginvestors.blogspot.com/2019/05/ones-to-watch-in-may.html?m=1
Now there are hundreds, if not thousands, of products that need a quick solution to allow their products to stay on the shelves and that requires a fast-track approach I expect Labskin will be announcing a disruptive solution to address this in the Clinical research space shortly

I’d imagine the initial targets will be existing clients and the approach would be with the current Client context setting up a meeting or call with the relevant people. Once some have been secured I’d think case studies would be produced to target new clients a mixture of sales and marketing. First and foremost secure the low hanging fruit that will make the tricker and more expensive wins more achievable and less pressure as additional revenues coming in from existing.

I understand profit taking is always understandable but the potential here is massive so I’m sure those taking profit are top slicing. Some tweets and replies.

CEO -
The recent EU Medical Device Directive Rule 21 imposes a requirement to test ingredients absorbed into the skin. The US FDA is likley to push further. See their FDA Experts opinion. More tests for Labskin?

Shareholder - Only just got round to looking the above up. So in order to remain on shelves the products need to have these tests before May 2020. A decent window and one in which #SKIN will have to start exploiting soon. I’m sure we will!

Of course any cos planning on launching new products after that date are a target but plenty of existing ones to go after between now and the end of May. Should keep #SKIN and its great team busy.

Both tweets liked by Gerry. He then replies -
What is quite interesting is that the companies who need #integumen to comply with the #SKIN tests are the ones who can afford it, and not just early-stage or Startups

Shareholder -

Indeed a captive market (by necessity) with deep pockets. No need to persuade the FD/CFO to spend the money as it’s the only way to keep their products on shelves beyond May 2020 and the powers that be would prefer to spend less which is where #Integumen comes in. A win win.

Sounds good to me!

From Gerry on Twitter -

Nice update to the original blog post on #SKIN #integumen from @LEMMINGINVESTOR lemminginvestors.blogspot.com/2019/05/ones-t…

First is Integumen (SKIN - 1.44p bid) which is showing signs that new management are guiding the company in the right direction. It has proven to be a very popular company on the blog, with over 1800 unique reads since 18th April. So what am I expecting the driver to be, after all, there appears to have been a seller dripping 25 million shares into the market instead of doing the sensible thing...pick up the phone to your broker - idiot! Anyway, there are buyers looking to accumulate the shares from the weak holder, me being one of those happy to add as funds allow. I can't say it is anything specific which will set the boosters off, rather an accumulation of developments the company has underway which I believe will attract interest from potential investors sitting on the fence collecting splinters for their troubles, and perhaps investors like me adding as the feeling of derisking becomes more obvious.

Speaking to CEO. Gerrad Brandon over the weekend, he says; " I am fixated on commercialising the science that already works and expects major disruptive news for Clinical Service Providers." So I expect to maintain the increased forward momentum the company is generating.

I am hopeful a large corporate will confirm strong clinical data for Labskin via a science presentation for skin and cosmetic products. As we know, this is a huge growth area around the world.

Gerrard explains further: As a consequence of EU 2017/745 Rule 21- Tests are now required for substances intended to be introduced into the human body via a body orifice or applied to the skin and that are absorbed by or locally dispersed in the human body. Basically, what this means for any product, that up to now was seen as safe, can no longer be relied on to be so. This means that the likes of ear-wax, nasal products, female hygiene products (tampons), medicated shampoos and medicated soaps and mouthwashes that can enter the body, have to be tested to ensure the products' ingredients do not cross the skin barrier. If they do, they are safe to do so. This recent rule has seen every product manufacturer having to comply with testing that they previously did not need, and the reclassification of their consumer products as medical devices.

Now there are hundreds, if not thousands, of products that need a quick solution to allow their products to stay on the shelves and that requires a fast-track approach I expect Labskin will be announcing a disruptive solution to address this in the Clinical research space shortly

Balance sheet looking very healthy and the money brought in is fuel for growth.

2017 new EU regs came in and any skin care products has to have skin testing.Labskin model reduces volunteers and the cost in half.

Going into CRO space - half price for client,creating new business and more revenue per client(from existing clients).

Gerry is building a monster here!

Also he said in the podcast around 22 mins in they’ll be doing the above which increases the total addressable market with limited marketing costs as they’ll sell to existing clients. I expect news before 13th, he implied in a tweet they’d be little point in presenting if it was the same material as podcast. An RNS on 13th or possibly before.

You’ll always get some taking a quick profit and judging by Friday the flippers are gone and we’re hopefully out of the downtrend. Better still I can’t see an RNS not being released before or the presentation on 13th as why bother. The CEO has implied that in a tweet so hopefully good news by 7am a week today. Hopefully even with the additional shares the recent high can be challenged. We’re increasing the TAM and the CEO again implied in Friday’s podcast that we’re looking at new targets and ones where we can target existing clients so marketing spend not really needed. Specifically he said 2017 new EU regs came in and any skin care products has to have skin testing.Labskin model reduces the number of volunteers needed and reduces the testing costs by half. That has to appeal. Lots of current clients to target. Exciting times.

I don’t believe they’re liable as I believe they resigned due to Zaza telling half truths re the CLN interest payment conditions. That is more than a little material so I believe Zaza is liable for withholding that info from the market and should be pursued if this goes belly up.

I blame Zaza and Nicandros. Absolute clowns in my view. If this goes tits up I’ll go after them for withholding material info which would have affected my investment decision. That’s why the NOMAD resigned.

Worth looking at advfn, although Lighstep is a boring, juvenile **** with his/her constant LOLs there are some snippets from the court docs albeit all negative.

Agreed.

Sales and marketing for Labskin/RinoCloud £0.21m
Working capital £1.64m
Also with STOER at break even and will hopefully be in the black come FY things are looking positive. Labskin has momentum and with additional marketing spend for new clients and generating sales from existing clients H2 should be really positive

Ha!

I was going to buy some BLOE at 3p but thought once bitten twice shy re Georgia and now over 12p and showing FRR how it’s done. Hopefully we get some long awaited positive news and soon.

https://gallery.mailchimp.com/d9ebd7c1aa0f3dbc5fab42eca/files/96e8af63-fc9c-42b6-a5d0-5e1305d18891/Integumen_29_April_2019_.pdf

How poorly managed FRR has been over the years. Look at BLOE, we should’ve been producing decent BOPD years ago. The NOMAD clearly resigned due to the emails being published and specifically due to material info being withheld which should’ve been subject to an RNS. The interest on the CLNs could no longer be added to the notes but to be paid in cash which was not disclosed so Cairn had little choice. It’s no coincidence they resigned the next trading day after the emails were published.

It’s a massive fucking mess and Zaza looks to have overplayed his/our hand. I hope that’s not the case but little wonder the GG want rid of these muppets. I hope we get a settlement and BP or BH buy us out lock stock and to get the £300m spent would do me fine so some £230m to be returned as a special dividend, 1.4p or so. Probably too good to be true.

He is, sad little prick.

Know what you mean but this section interested me-

The only question when the Judge finds out the truth will be did SN conceal from Eric Fisher the facts about the Cayman proceedings and therefore SN faces perjury charges for page 9 lines 18 to 22 or did Eric know and decide to omit the material truth and risk a severe censure definitely and possible disbarment for suborning perjury. My guess would be it is the former - even a first year law student would not be so stupid.

Out and about so can’t access docs easily, any thoughts?

FRR have fucking lied yet again and this time SN could face perjury charges.

Read the TRO motion page 9 lines 18 to 22.

Judge K robustly found FRR had no chance of success in the fiduciary duties case, which is why he lifted the injunction. He said FRR could appeal the lifting of the injunction and FRR might be lucky with the appeal. FRR did not bother to appeal and instead filed the fiduciary duties complaint in California. The failure to appeal meant the stay of execution on the lifting of the Cayman injunction ended. OMF have therefore exercised their rights under their "bionic" contract. FRR have filed for the TRO. There is no way FRR can claim to be unsure of where to file when they already have a robust finding they will lose in Cayman and then go on to state there is no material difference between Cayman and California law in this regard and then claim to have met the requirement for demonstrating they have a good chance of success.

I can't see anywhere in the TRO motion making it ex partie, so OMF's lawyers will be in court when the judge hears arguments from both sides (OMF are still within the 21 days they have to respond to the original complaint and I guess the clock is reset by the amendment - so the TRO hearing will be the first time OMF are heard in California). The only question when the Judge finds out the truth will be did SN conceal from Eric Fisher the facts about the Cayman proceedings and therefore SN faces perjury charges for page 9 lines 18 to 22 or did Eric know and decide to omit the material truth and risk a severe censure definitely and possible disbarment for suborning perjury. My guess would be it is the former - even a first year law student would not be so stupid.

I would love to be able to sit in the court when the TRO hearing occurs, it would be well worth the air fare to get there for sheer entertainment value, but I will have to satisfy myself with the transcript when it becomes available.